181 related articles for article (PubMed ID: 15789912)
1. [The effect of one-month antithyroid therapy on peripheral metabolism of reactive oxygen species in Graves' disease with infiltrative ophthalmopathy].
Bednarek J; Wysocki H; Sowiński J
Przegl Lek; 2004; 61(8):841-4. PubMed ID: 15789912
[TBL] [Abstract][Full Text] [Related]
2. Peripheral parameters of oxidative stress in patients with infiltrative Graves' ophthalmopathy treated with corticosteroids.
Bednarek J; Wysocki H; Sowiński J
Immunol Lett; 2004 May; 93(2-3):227-32. PubMed ID: 15158621
[TBL] [Abstract][Full Text] [Related]
3. Oxidative stress peripheral parameters in Graves' disease: the effect of methimazole treatment in patients with and without infiltrative ophthalmopathy.
Bednarek J; Wysocki H; Sowiński J
Clin Biochem; 2005 Jan; 38(1):13-8. PubMed ID: 15607311
[TBL] [Abstract][Full Text] [Related]
4. Oxidation products and antioxidant markers in plasma of patients with Graves' disease and toxic multinodular goiter: effect of methimazole treatment.
Bednarek J; Wysocki H; Sowinski J
Free Radic Res; 2004 Jun; 38(6):659-64. PubMed ID: 15346657
[TBL] [Abstract][Full Text] [Related]
5. Serum levels of the interferon-gamma-inducible alpha chemokine CXCL10 in patients with active Graves' disease, and modulation by methimazole therapy and thyroidectomy.
Antonelli A; Fallahi P; Rotondi M; Ferrari SM; Serio M; Miccoli P
Br J Surg; 2006 Oct; 93(10):1226-31. PubMed ID: 16838393
[TBL] [Abstract][Full Text] [Related]
6. Relation between therapy for hyperthyroidism and the course of Graves' ophthalmopathy.
Bartalena L; Marcocci C; Bogazzi F; Manetti L; Tanda ML; Dell'Unto E; Bruno-Bossio G; Nardi M; Bartolomei MP; Lepri A; Rossi G; Martino E; Pinchera A
N Engl J Med; 1998 Jan; 338(2):73-8. PubMed ID: 9420337
[TBL] [Abstract][Full Text] [Related]
7. Oxidative stress profile in graves' ophthalmopathy in Indian patients.
Kaur A; Pandey S; Kumar S; Mehdi AA; Mishra A
Orbit; 2010 Apr; 29(2):97-101. PubMed ID: 20394549
[TBL] [Abstract][Full Text] [Related]
8. Methimazole protection against oxidative stress induced by hyperthyroidism in Graves disease.
Sewerynek J; Wiktorska J; Nowak D; Lewinski A
Endocr Regul; 2000 Jun; 34(2):83-9. PubMed ID: 10911409
[TBL] [Abstract][Full Text] [Related]
9. Antioxidants and methimazole in the treatment of Graves' disease: effect on urinary malondialdehyde levels.
Guerra LN; Ríos de Molina Mdel C; Miler EA; Moiguer S; Karner M; Burdman JA
Clin Chim Acta; 2005 Feb; 352(1-2):115-20. PubMed ID: 15653105
[TBL] [Abstract][Full Text] [Related]
10. Peripheral parameters of oxidative stress in Graves' disease: the effects of methimazole and 131 iodine treatments.
Abalovich M; Llesuy S; Gutierrez S; Repetto M
Clin Endocrinol (Oxf); 2003 Sep; 59(3):321-7. PubMed ID: 12919155
[TBL] [Abstract][Full Text] [Related]
11. The balance shift in Th1/Th2 related IL-12/IL-5 cytokines in Graves' disease during methimazole therapy.
Molnár I
Autoimmunity; 2007 Feb; 40(1):31-7. PubMed ID: 17364495
[TBL] [Abstract][Full Text] [Related]
12. Serum IL-18 levels are not increased in patients with untreated Graves' ophthalmopathy.
Wakelkamp IM; Prummel MF; Wiersinga WM
Horm Metab Res; 2004 Jan; 36(1):44-7. PubMed ID: 14983406
[TBL] [Abstract][Full Text] [Related]
13. The distribution of the major peripheral blood T, B and NK cell subsets does not predict the clinical outcome of Graves' disease patients after methimazole therapy.
Corrales JJ; López A; Ciudad J; Orfao A
J Biol Regul Homeost Agents; 2000; 14(3):193-9. PubMed ID: 11037052
[TBL] [Abstract][Full Text] [Related]
14. [Titers of antibodies against thyroid membrane antigens in patients with Graves-Basedow disease and progressive infiltrative ophthalmopathy during treatment with glucocorticoids and retro-orbital tissue irradiation].
Pilarska K; Syrenicz A; Czekalski S; Gołebiowska I; Andrzejewska W; Krzystolik Z
Pol Tyg Lek; 1991 Oct 28-Nov 4; 46(43-44):824-6. PubMed ID: 1669170
[TBL] [Abstract][Full Text] [Related]
15. Oxidative stress and antioxidant activity in orbital fibroadipose tissue in Graves' ophthalmopathy.
Hondur A; Konuk O; Dincel AS; Bilgihan A; Unal M; Hasanreisoglu B
Curr Eye Res; 2008 May; 33(5):421-7. PubMed ID: 18568878
[TBL] [Abstract][Full Text] [Related]
16. Changes of serum cytokines in hyperthyroid Graves' disease patients at diagnosis and during methimazole treatment.
Pedro AB; Romaldini JH; Takei K
Neuroimmunomodulation; 2011; 18(1):45-51. PubMed ID: 20628263
[TBL] [Abstract][Full Text] [Related]
17. Increase of interferon-gamma-inducible CXC chemokine CXCL10 serum levels in patients with active Graves' disease, and modulation by methimazole therapy.
Antonelli A; Rotondi M; Fallahi P; Romagnani P; Ferrari SM; Barani L; Ferrannini E; Serio M
Clin Endocrinol (Oxf); 2006 Feb; 64(2):189-95. PubMed ID: 16430719
[TBL] [Abstract][Full Text] [Related]
18. [Antibodies against TSH receptors (TRAb) as indicators in prognosing the effectiveness of Tiamazol therapy for Grave's Disease].
Bojarska-Szmygin A; Ciechanek R
Wiad Lek; 2003; 56(7-8):303-7. PubMed ID: 14969154
[TBL] [Abstract][Full Text] [Related]
19. Protective effect of silymarin on erythrocyte haemolysate against benzo(a)pyrene and exogenous reactive oxygen species (H2O2) induced oxidative stress.
Kiruthiga PV; Shafreen RB; Pandian SK; Arun S; Govindu S; Devi KP
Chemosphere; 2007 Jul; 68(8):1511-8. PubMed ID: 17481694
[TBL] [Abstract][Full Text] [Related]
20. Activity of antioxidative enzymes and concentration of malondialdehyde as oxidative status markers in women with newly diagnosed Graves-Basedow disease and after thiamazole therapy leading to euthyroidism.
Rybus-Kalinowska B; Zwirska-Korczala K; Kalinowski M; Kukla M; Birkner E; Jochem J
Pol Arch Med Wewn; 2008; 118(7-8):420-5. PubMed ID: 18714737
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
